Edgewise Therapeutics Q4 2023 Earnings Report
Key Takeaways
Edgewise Therapeutics reported fourth-quarter financial results, with R&D expenses at $27.7 million and G&A expenses at $6.2 million. The net loss for the quarter was $30.1 million, or $0.47 per share. The company's cash, cash equivalents, and marketable securities totaled approximately $318.4 million as of December 31, 2023, excluding $231.8 million in net proceeds from a January 2024 underwritten offering.
Advanced the global pivotal cohort, GRAND CANYON, of EDG-5506 in Becker muscular dystrophy (Becker).
Advanced Phase 2 LYNX trial of EDG-5506 including new cohort for boys with Duchenne muscular dystrophy (Duchenne) not currently treated with corticosteroids.
Initiating Phase 2 FOX trial in boys with Duchenne who have been previously treated with gene therapy.
Advanced Phase 1 trial of EDG-7500, a novel cardiac sarcomere modulator for hypertrophic cardiomyopathy (HCM), and other serious diseases of cardiac diastolic dysfunction.